Equity research analysts from major global investment banks and healthcare-focused brokerage firms cover Bicycle Therapeutics (NASDAQ: BCYC). These institutional financial professionals publish regular research reports, rating assessments, and 12-month forward price targets based on clinical trial progress, partnership milestones with major pharmaceutical enterprises, and balance sheet cash burn evaluations.